Carmine Therapeutics develops a novel type of gene therapy that utilizes extracellular vesicles produced in the laboratory.
Carmine Therapeutics's investors include Huagai Capital, Simcere Pharma, Cystic Fibrosis Foundation, Esco Ventures, EVX Ventures.
Carmine Therapeutics is headquartered in Cambridge, United States.
Carmine Therapeutics develops a novel type of gene therapy that utilizes extracellular vesicles produced in the laboratory.
Carmine Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Carmine Therapeutics — Funding & Investors." VCBacked, October 13, 2022, https://www.vcbacked.co/company/carmine-therapeutics. Accessed September 30, 2026.
VCBacked. (2022). Carmine Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/carmine-therapeutics
{{cite web |title=Carmine Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/carmine-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated